

# UNGA AMR AWaRe and the 70% Access antibiotic target

**Professor Mike Sharland** 

**Antibiotic Policy Group** 

City St George's, University of London





# UNGA-AMR 2024 Declaration UHC/SDG approach

63. Invest in sustainable and resilient health systems, based on a primary health care approach, to support universal access to essential health services and promote the timely and equitable supply of quality and affordable vaccines, diagnostics and treatments, including antimicrobials, and ensure their appropriate use <u>including by applying or adapting the WHO Access, Watch and Reserve (AWaRe)</u> classification of antibiotics within national contexts;



### ACCESS GROUP

 first or second choice antibiotics
 offer the best therapeutic value, while minimizing the potential for resistance

# WATCH

first or second choice antibiotic.
 only indicated for specific, limit number of infective syndromes
 more prone to be a target of antibiotic resistance and thus prioritized as targets of stewardship programs and

## RESERVE GROUP

"last resort"
highly selected patients (life-threatening infections due to multi-drug resistant bacteria)
closely monitored and prioritizes as targets of stewardship programs to ensure their

### Political Declaration of the High-level Meeting on Antimicrobial Resistance

We, Heads of State and Government and representatives of States and Governments, are assembled at the United Nations on 26 September 2024, in accordance with General Assembly resolution 78/269, to review progress on global, regional and national efforts to tackle antimicrobial resistance, to identify gaps and invest in sustainable solutions to strengthen and accelerate multisectoral progress at all levels, through a One Health approach, with a view to scaling up the global effort to build a healthier world based on equity and leaving no one behind, and in this regard we:

64. Ensure, by 2030, that the <u>use of WHO Access group antibiotics is</u> <u>expanded from the 2023 global target, and in that regard, taking into account national contexts, aim to achieve at least 70 per cent overall <u>human antibiotic use globally</u>, through investing in and strengthening stewardship programmes,</u>

70% of global antibiotic use should be Access antibiotics



Country-level targets & implementation still needed






# AWaRe Now

• First dose of penicillin 12<sup>th</sup> February 1941 today ~40-50 billion daily doses of antibiotics

- WHO AWaRe <u>system</u>
  - WHO 2023 Essential Medicines List 41 Antibiotics total
  - 257 antibiotics being used (have an AWaRe group)
  - 2022 WHO AWaRe Antibiotic Book
- Hospital use is an important but relatively <u>small</u> part of total antibiotic use
  - 90% of use is oral antibiotics in primary care
  - 10% of use is parenteral (IV/IM) in hospitals
- GLASS AMU 2022 Access 52.7%, Watch 45.3%, NR/NC 1.7%, Reserve 0.3% (60 CTAs)
- Generic antibiotic market not broken 40-50 billion
   USD annual compound growth 4-5%
- Cost savings with increasing Access use

On EML 20 Access 12 Watch

9 Reserve





# AWaRe Future

- Antibiotic policy <u>and</u> stewardship
  - Population <u>and</u> patient level interventions
  - Primary care **and** hospitals
  - AWaRe MAP Global Action Plan
- Relative cost effectiveness of direct and indirect interventions
- Universal access to key essential AWaRe antibiotics
- One Health Vet AWaRe, wide engagement including manufacturers
- AMR Medicines Management and Policy global supply chains
- Define optimal levels of sustainable antibiotic use based on population health need – IPEA

# **M**onitoring

 Integrating existing national and global data sources

# **A**nalysis

- Relative (%) & Absolute (DID) AWaRe Use
- Population health needs

# **Policy**

- National assessments to inform multiple policy options
- Shared learning across NAPs



